Create game-changing, long-lasting treatments for patients with cancer by effective mobilization of the immune system coupled with novel patient selection strategies

Learn More


Novel paradigm of integrating clinical insights into each aspect of drug discovery and development

Learn More


Couple each product candidate with patient selection strategies

Learn More

A Revolutionary Approach to Cancer Treatment

jounce sqwiggle

We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.

better cancer treatments

Mobilizing the Immune System to Attack Cancer

Our research and development strategy is to target specific mechanisms that match the composition of the immune system within the human tumor microenvironment (TME), with the goal of transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and bring long-lasting benefits to patients.

Our lead program, JTX-2011 – an ICOS agonist monoclonal antibody - complements existing cancer immunotherapies, such as anti-PD-1 therapies, by binding to and activating ICOS, stimulating an immune response against the cancer.

We are also developing treatments that target other immune cells – "Beyond T cells" – in order to help patients whose tumors are driven by mechanisms, such as immune-suppressive macrophages.



Coley's toxins

First cancer vaccine developed (Coley's "toxins")


coley's work

Coley’s work first published. In the late 19th century, William Coley injected bacterial extracts into multiple patients suffering from bone or soft tissue sarcomas and over several decades reported responses or complete remissions in a substantial fraction of them (Cell, 2015)



Immunotherapy largely dismissed as a viable avenue to treat cancer

1960's - 1990's

t cells

Co-stimulatory pathways on T cells described by Peter Linsley, Jim Allison and Jeffrey Bluestone

Early 1990's

pd-1 receptor

PD-1 receptor (immune checkpoint) identified by Tasuku Honjo



IFN-α approved as adjuvant therapy (additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back)


preclinical evidence ctla-4

Preclinical evidence from Jim Allison of enhanced anti-tumor immunity by CTLA-4 published in Science

Learn More


jounce founders publish

Brad Carthon and Jounce founders Pam Sharma & Jim Allison’s publication on enhanced survival related to up-regulation of ICOS on T cells in Clinical Cancer Research

Learn More



Yervoy® anti-CTLA-4 approved for advanced melanoma


Jounce Launches

Jounce launched by Third Rock Ventures and founders, James P. Allison, Ph.D., Thomas F. Gajewski, M.D., Ph.D., Drew Pardoll, M.D., Ph.D., Padmanee Sharma, M.D., Ph.D., Louis M. Weiner, M.D.

February 2013

Jounce expands application

Jounce expands application of translational science platform to Beyond T cells and initiates series of programs targeting myeloid and other cell types


Keytruda and Opdivo

Keytruda® and Opdivo® (Anti-PD-1), (immune checkpoint therapies) approved; additional clinical trials indicate activity in several cancers



Jounce declares first development candidate, JTX-2011, an agonist mAb targeting ICOS

January 2015

Jim Allison

Jounce founder, Jim Allison receives the Lasker-DeBakey Clinical Medical Research Award


Scroll to Learn More

"If curing cancer wasn’t motivation enough, then working with some of the smartest people in the industry is. I feel humbled to work with such brilliant people who are striving to touch the lives of others in a huge way."

- Sharon Morani, Executive Assistant/Manager of Administration, Operations

"We have a fantastic group of scientists who have specialized knowledge in the field and are highly collaborative. Each person brings something unique to the table, but together we can do amazing things."

- Tyler Simpson, Senior Scientist, TME Group

"We feel united by a common purpose. Jounce is not just another follow-on drug discovery company – the people at Jounce are pioneers who are truly focused on making a difference for patients."

- Todd Rowe, Informatics Manager, IT & Informatics


We are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that dramatically impact and improve patients' lives

Nov 17, 2015

Jounce Therapeutics Appoints Duncan Higgons to Its Board of Directors

Read More

Nov 3, 2015

Jounce Therapeutics Appoints Elizabeth Trehu, M.D., to Chief Medical Officer

Read More

Oct 1, 2015

Jounce Therapeutics Announces Presentation at the Leerink Partners Immuno-Oncology Roundtable

Read More